ACCESS Newswire

Cactus Life Sciences

Share
Cactus Life Sciences Announces Appointment of Oliver Dennis as Chairman to Shape the Agency of the Future

Fishawack Health Founder's Deep History in Healthcare Communications Blends Nicely with Global Scientific Communications Agency's Upcoming Buy-and-Build Strategy

PRINCETON, NJ / ACCESSWIRE / April 16, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that Oliver Dennis has joined them as Chairman, to work alongside Co-founder, Anurag Goel.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Oliver Dennis, Chairman of Cactus Life Sciences

Cactus Life Sciences, headquartered in Princeton, New Jersey was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. "We're delighted to have someone with Oliver's experience of growing businesses join the team," said Anurag. "Cactus Life Sciences is about to undertake an exciting buy and build strategy. And Oliver is the perfect addition with his deep history in healthcare communications having founded Fishawack Health® (now Avalere®)."

During Oliver's tenure at Fishawack, he acquired 17 businesses over 13 years including medical communications and branding agencies, as well as strategic healthcare consultancies and market access and HEOR advisory firms. He led 4 management buy outs to take the business from a start-up to over 1400 people across 22 offices, spanning San Diego to Singapore. Oliver will specifically help shape the future vision for Cactus Life Sciences as the healthcare communications agency partner of the future (strategic, agile, tech-enabled, and outcomes focused) to take on traditional agencies which have lost agility and identity in the pursuit of maximizing profit. He will play an active role in driving the inorganic growth strategy for the business, while pursuing his passion for bringing people together from different businesses and disciplines to collaborate on better outcomes for clients, patients, and our people.

"I've been following Cactus over the last 10 years and they're a great organization. I'm excited to be joining them. They've grown consistently and they have the ambition to become the next generation challenger brand to the traditional players in the market," said Oliver. "This is an opportunity to do something with a greater focus on solving client challenges, improving health outcomes, and nurturing our people."

"Too many companies get to a size where they lose their sense of purpose, values, and forget about individuality. As we work toward transforming Cactus Life Sciences into an agency of the future, we want to ensure that we do so while ensuring that patients and our people are at the core of everything we do," said Elvira D'souza, President of Cactus Life Sciences.

About Cactus Life Sciences (cactuslifesciences.com) Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world─with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes. CACTUS has offices in Princeton, London, Aarhus, Singapore, Beijing, Shanghai, Seoul, Tokyo, and Mumbai.

Contact Information:

Laura Perry
Vice President of Strategy & Marketing
laura.perry@cactusglobal.com
7327121005

SOURCE: Cactus Life Sciences

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

New GTDC Report Highlights Effective Methods for Building Optimal Channel Strategies2.12.2025 15:00:00 CET | Press release

TAMPA, FL / ACCESS Newswire / December 2, 2025 / The Global Technology Distribution Council (GTDC) has released a groundbreaking new industry study titled "Building the Optimal Distribution Strategy." This comprehensive guide provides insights and valuable best practices for evaluating market and channel coverage needs and determining which types of distributors provide the best fit for technology suppliers. Former global channel chief and partner route to market specialist Donna Grothjan led the development of this member-inspired GTDC project, adding her personal knowledge and experience creating and managing distribution strategies, as well as gathering and sharing insight from respected industry peers and subject matter experts. Distribution remains the most cost-effective route-to-market for technology suppliers. That value is rising rapidly in the cloud era as emerging and legacy vendors look to scale sales, support and other operations around these virtual offerings without requ

GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases2.12.2025 06:00:00 CET | Press release

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / December 2, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today. SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases. This Phase 1 randomized, d

TheaMou by Theo Announces Global Revival of the Original Olympic Games and Operation PAME BROSTA at Athens Fashion Week26.11.2025 19:00:00 CET | Press release

TheaMou Ignites Athens Fashion Week with a Goddess-Warrior Revival Rooted in Ancient Greece ATHENS, GREECE / ACCESS Newswire / November 26, 2025 / TheaMou by Theo ("My Goddess" in Greek), the creative umbrella uniting MeaDea by Theo, Iellele by Theo, MiDiosa by Theo, and aligned cultural initiatives, presented its Ancient Greek Goddess & Warrior Collection at Athens Fashion Week on November 14th, 2025. Founder, Sam Stathis, used the Athens Fashion Week stage to officially launch operation PAME BROSTA (Moving forward in Greek) and announce the global revival of the ORIGINAL OLYMPIC GAMES.Sam Stathis with Olympic Angels at Athens Fashion Week Sam Stathis with Olympic Angels and TheaMou by MeaDea models at Athens Fashion Week Three Olympic Angels by Theo, each a crowned national beauty queen (Miss Greece-Star Hellas, Stella Mihailidou, Miss Italia, Federica Rizza, and Miss Netherlands, Elize DeJong), opened the runway show, symbolizing the revival of the True Flame of Greece through divin

Clean Air Metals Files PEA Technical Report for the Thunder Bay North Critical Minerals Project24.11.2025 13:00:00 CET | Press release

THUNDER BAY, ON / ACCESS Newswire / November 24, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to announce that it has filed the Preliminary Economic Assessment (PEA) and updated resource that was completed for its Thunder Bay PGE-Cu-Ni Project near Thunder Bay, Ontario, Canada. The results of the PEA and resource were previously disclosed in the Company's news release dated October 9th, 2025. The PEA outlines an 11-year mine life (+ 2 years of pre-production activities) producing 2,500 tonnes per day from a near-surface, ramp-access underground operation. The report is available under the Company's profile at www.Sedarplus.ca and will be available on the Company's website at www.cleanairmetals.ca. All figures are in Canadian Dollars, unless specified otherwise. Highlights The project has a $219.4M1 pre-tax NPV8 against a project capital cost of $89.5M. After-tax NPV of $157.5M The pre-tax internal rate of return (IRR) is

Capital.com Strengthens European Operations with Expanded Customer Service Hub in Bulgaria24.11.2025 09:00:00 CET | Press release

Reports trading volumes of $744 billion in Q3 2025 SOFIA, BG / ACCESS Newswire / November 24, 2025 / Capital.com, the high-growth trading platform and fintech group, today announced the expansion of its operations in Bulgaria with the opening of a new office at Sofia's Office X Business Garden and a 51% increase in local headcount over the past year. This development aligns with the company's strategy to build specialised centres of excellence across key functions, with Bulgaria leading the way in customer service. Building on its established presence in Sofia and complementing its technology hub in Poland, Capital.com plans to invest up to €5 million into its operational infrastructure to create a centre of excellence for customer service and one of the best workplace experiences in the industry. The Bulgaria hub will set the gold standard for service quality, responsiveness, and multilingual support, playing a pivotal role in supporting clients worldwide while fostering a culture of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye